The trial will examine if upadacitinib and pirfenidone can be repurposed to reduce or eliminate symptoms of long COVID
Spanning four continents and enrolling hundreds of people, a new clinical trial will test the effectiveness of two anti-inflammatory medicines as potential treatments for long COVID, scientists from Western University and the Schmidt Initiative for Long Covid (SILC) announced today